General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded without agreement
Manufacturer:
HLS Therapeutics Inc.
Indication:
Schizophrenia
Last updated June 1, 2022
Status:
Concluded without agreement
Manufacturer:
M�dunik Canada Inc.
Indication:
Lambert-Eaton Myasthenic Syndrome (LEMS)
Last updated June 1, 2022
Phesgo SC (perjeta and herceptin)
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic breast cancer (HER2-positive) first-line treatment
Last updated May 19, 2022
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Extensive-stage small cell lung cancer (ES-SCLC) in adult patients, first-line treatment (in combination with etoposide and either carboplatin or cisplatin)
Last updated May 18, 2022
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated May 17, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated May 16, 2022
Status:
Concluded with an LOI
Manufacturer:
Organon Canada Inc.
Indication:
Metastatic breast cancer (HER2-positive) in patients with who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)
Last updated May 16, 2022
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib
Last updated May 13, 2022
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated May 10, 2022
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated May 10, 2022